Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7992380 | 0.98 | ALDH1A1 (0.32) | ALDH1A1RAB9A | |
| SCHEMBL7991290 | 0.98 | ALDH1A1 (0.32) | ALDH1A1RAB9A | |
| SCHEMBL316395 | 0.94 | — | — | |
| SCHEMBL791251 | 0.88 | PSMB5 (0.31) | ALDH1A1RAB9A | |
| SCHEMBL9211200 | 0.86 | FAAH (0.33) | ALDH1A1RAB9A | |
| SCHEMBL61668 | 0.85 | TSHR (0.33) | — | |
| SCHEMBL68779 | 0.85 | — | — | |
| SCHEMBL7980376 | 0.83 | CXCR3 (0.33) | ALDH1A1RAB9A | |
| SCHEMBL177598 | 0.83 | CXCR3 (0.33) | ALDH1A1RAB9A | |
| SCHEMBL9213136 | 0.82 | TSHR (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0227241-B1 | Medicinal indole and indazole keto sulphone derivatives | ZENECA INC (US) | 1996-09-11 | — | — | EP | claimed |
| US-5234942-A | Treating allergic pulmonary disorders, asthma | ICI AMERICAS INC. (US) | 1993-08-10 | — | — | US | claimed |
| EP-0242167-B1 | HETEROCYCLIC CARBOXAMIDES | ICI AMERICAS INC. (US) | 1991-11-27 | — | — | EP | claimed |
| US-4997844-A | Compounds for the treatment of allergic or inflammatory diseases or shock conditions | ICI AMERICAS INC. (US) | 1991-03-05 | — | — | US | claimed |
| EP-0179619-B1 | HETEROCYCLIC AMIDES | ICI AMERICAS INC. (US) | 1990-09-05 | — | — | EP | claimed |
| US-4898863-A | Heterocyclic carboxamides | ICI AMERICAS INC. (US) | 1990-02-06 | — | — | US | claimed |
| US-4837235-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | ICI AMERICAS INC. (US) | 1989-06-06 | — | — | US | claimed |
| CN-87103504-A | Heterocyclic carboxamide | — | 1987-12-09 | — | — | CN | claimed |
| EP-0242167-A2 | Heterocyclic carboxamides | ICI AMERICAS INC. (US) | 1987-10-21 | — | — | EP | claimed |
| EP-0227241-A2 | Medicinal indole and indazole keto sulphone derivatives | ZENECA INC. (US) | 1987-07-01 | — | — | EP | claimed |
| CN-85108623-A | Preparation has the novel method of the heterocycleamide of medical active | — | 1986-07-30 | — | — | CN | claimed |
| EP-0179619-A1 | Heterocyclic amides | ICI AMERICAS INC. (US) | 1986-04-30 | — | — | EP | claimed |
| WO-2024106539-A1 | LIGAND CONJUGATE SUBSTANCE, NUCLEIC ACID CONTAINING SAME, AND USE THEREOF | 株式会社ボナック | 2024-05-23 | — | — | WO | disclosed |
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| EP-4206325-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-20230183283-A1 | NOVEL GLYCOSIDE COMPOUND AND PRODUCTION METHOD THEREFOR | BONAC CORPORATION (JP) | 2023-06-15 | — | — | US | disclosed |
| EP-0220066-A2 | Carboxamide derivatives | ICI AMERICAS INC. (US) | 1987-04-29 | — | — | EP | disclosed |
| CN-86103278-A | The method for preparing heterocyclic amide derivative | — | 1986-12-17 | — | — | CN | disclosed |
| EP-0199543-A2 | Heterocyclic amide derivatives | ICI AMERICAS INC. (US) | 1986-10-29 | — | — | EP | disclosed |
| EP-0179619-A1 | Heterocyclic amides | ICI AMERICAS INC. (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | SNRPE, DDX21, DCLRE1B | ALDH1A1 3438/4885RAB9A 3603/4885 |
| US-20230183283-A1 | NOVEL GLYCOSIDE COMPOUND AND PRODUCTION METHOD THEREFOR | SLC5A11, POLRMT, MAPK11 | ALDH1A1 3258/4885RAB9A 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.